
Guanghui Wang
Articles
Optical enantioseparation of chiral nanoparticles in macroscopic scale within a microfluidic channel
Dec 21, 2024 |
opg.optica.org | Guanghui Wang
In this Letter, we have proposed an all-optical scheme for chiral particle separation with a microcylinder-pair system (MCPS) with a micrometer scale channel, applicable in microfluidic environments. By illuminating the MCPS with two counter-incident plane waves of orthogonal polarization, the electromagnetic chirality gradient can be generated.
-
Dec 20, 2024 |
mdpi.com | Guanghui Wang
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle by Jie Liu †, Yang Xu †, Guobin Xie, Bingjie Geng, Renjing Yang, Wenjing Tian, Haifeng Chen * and Guanghui Wang * School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China *Authors to whom correspondence should be addressed. †These authors contributed equally to this work. Int. J. Mol. Sci.
-
Dec 18, 2024 |
pubs.rsc.org | Guanghui Wang
3D-printed acoustic metasurface with encapsulated micro-air-bubbles for frequency-selective manipulation† Acoustic waves provide an effective method for object manipulation in microfluidics, often requiring high-frequency ultrasound in the megahertz range when directly handling microsized objects, which can be costly. Micro-air-bubbles in water offer a solution toward low-cost technologies using low-frequency acoustic waves.
-
Apr 16, 2024 |
arxiv.org | Guanghui Wang
-
Aug 18, 2023 |
nature.com | Yadong Wang |Guanghui Wang
AbstractOsimertinib is a promising approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for treating patients with lung adenocarcinoma (LUAD) harboring EGFR-activating mutations, however, almost all patients develop resistance to Osimertinib eventually limiting the long-term efficacy. Autophagy is a vital cellular recycling process promoting Osimertinib resistance.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →